FilingReader Intelligence
CSPC Pharmaceutical gets China approval for dupilumab biosimilar trials
August 19, 2025 at 09:40 AM UTC•By FilingReader AI
CSPC Pharmaceutical Group has received approval from China's National Medical Products Administration to commence clinical trials for its Dupilumab Injection, a biosimilar to Dupixent.
The recombinant fully human monoclonal antibody targets IL-4R α and is indicated for treating moderate-to-severe atopic dermatitis in adults. Non-clinical studies showed high similarity to the reference drug in quality, safety, and efficacy.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
HKEX:1093•Hong Kong Exchange
News Alerts
Get instant email alerts when CSPC Pharmaceutical Group publishes news
Free account required • Unsubscribe anytime